Biocrates Life Sciences AG joins SysKid
Biocrates Life Sciences AG has joined a multi-partner European research program dedicated to improving the diagnosis and treatment of chronic kidney disease (CKD), i.e., the ‘systems biology towards Novel Chronic Kidney Disease Diagnosis and Treatment’ project — or SysKid.
A large-scale integrative European research project, SysKid, has now set out to improve the early detection of CKD. Much of SysKid’s financial underpinning comes from a European Union grant amounting to EUR 11.8 million. The consortium, which held its first general assembly from 9–11 March 2010 at the Medical University of Vienna, brings together 25 research groups from 15 countries, i.e., Austria, Belgium, Denmark, France, Great Britain, Germany, Hungary, Italy, Israel, Ireland, Poland, Spain, Switzerland, the Netherlands, and the United States, and will extend over 5 years.
“The most exciting and innovative aspect of SysKid is that it makes use of a revolutionary area of research referred to as ‘systems biology’ — the biostatistical integration of data generated from genomics, transcriptomics, proteomics, and metabolomics,” says Dr. Klaus Weinberger, Chief Scientific Officer of Biocrates. “This ‘omics’ quartet will allow the development of novel diagnostic biomarkers of unprecedented specificity and sensitivity, painting a comprehensive and interdisciplinary picture of CKD—from the genetic basis of the disease to its expression, protein, and metabolite profile. This approach will enable CKD to be detected well before it has become manifest, assess disease stages more accurately, and tailor treatment to the individual needs of a patient.”
Other news from the department business & finance
